SELLAS Life Sciences Group, Inc. (SLS) Form 8-K — May 12, 2026
SELLAS Life Sciences Group, Inc. reported a net loss of $8.4 million, or $0.05 per share, for the first quarter of 2026, compared to a net loss of $5.8 million, or $0.07 per share, for the same period in 2025. The increase in net loss was primarily due to higher research and development expenses, which rose from $3.2 million to $5.1 million, and general and administrative expenses, which increased from $2.9 million to $4.1 million. The company announced that 78 events have occurred in the pivotal Phase 3 REGAL trial of Galinpepimut-S (GPS) in acute myeloid leukemia (AML) as of May 11, 2026.
Key figures
- Eps
- -0.05
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -8,407
- Total Debt
- 0
- Revenue Yoy
- 0
- Cash Position
- 107,097
- Shares Outstanding
- 172,481,541
- Total Assets
- 114,177
- Accounts Payable
- 3,633
- Total Liabilities
- 6,765
- Accumulated Deficit
- -283,395
- Total Current Assets
- 111,169
- Common Stock Authorized
- 350,000,000
- Total Operating Expenses
- 9,252
- Additional Paid In Capital
- 390,789
- Total Current Liabilities
- 6,456
- Total Non Operating Income
- 845
- Total Stockholders Equity
- 107,412
- Research And Development Expenses
- 5,129
- Common Stock Issued And Outstanding
- 181,332,574
- General And Administrative Expenses
- 4,123
- Restricted Cash And Cash Equivalents
- 100
- Prepaid Expenses And Other Current Assets
- 3,972
- Total Liabilities And Stockholders Equity
- 114,177
- Accrued Expenses And Other Current Liabilities
- 2,261
Price after filing
Close on the filing date to close N calendar days later (from $5.22). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.